Search Medical Condition
Please enter condition
Please choose location from dropdown

Chandler, Arizona Clinical Trials

A listing of Chandler, Arizona clinical trials actively recruiting patient volunteers.

RESULTS

Found (276) clinical trials

Evaluation of the Baha SoundArc in Pediatric Patients

Current Baha recipients that are using a Baha SoftBand will be recruited to be fitted with an alternative non-surgical option for using their Baha Sound Processor. The subjects will be tested with there existing Baha Sound Processor on the SoftBand and will then be fitted with the Baha SoundArc where ...

Phase N/A

2.08 miles

Learn More »

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Principal Investigators: The principal investigators (PIs) will be transplant physicians at all participating U.S. transplant centers. Study Design: This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. Primary Objective: The primary objective of ...

Phase N/A

2.08 miles

Learn More »

Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

Data (e.g. type of procedure, platelet count, etc.) will be collected retrospectively or prospectively from patient visits occurring within approximately 7 calendar days prior to the first dose of avatrombopag, on Procedure Day, on Discharge Day, and from any clinic visit performed up to 30 days post-procedure. All treatment decisions ...

Phase N/A

2.08 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Immunogenicity of V114 Followed by PNEUMOVAX 23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

This study is designed 1) to evaluate the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in healthy adults 50 years of age or older, 2) to describe the safety of sequential administration of V114 or Prevnar 13 followed by PNEUMOVAX23, and 3) to evaluate the immune responses to ...

Phase

2.08 miles

Learn More »

AMPLATZER PFO Occluder Post Approval Study

A maximum of 1214 adult subjects will be enrolled at up to 100 centers in the U.S. and Canada. Subjects will have follow-up at 1 month, 6 months, 12 months and annually thereafter through 5 years post implant.

Phase N/A

2.08 miles

Learn More »

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease.

Phase

2.08 miles

Learn More »

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Primary Objectives To evaluate the effect of seladelpar on hepatic fat fraction, as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at Week 12 To evaluate the safety and tolerability of seladelpar in subjects with NASH Secondary Objectives To evaluate the effect of seladelpar on hepatic fat fraction, as ...

Phase

2.08 miles

Learn More »

A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale

The primary objective of the study is to assess the responsiveness of the Brief Arthritis Stiffness Scale (BASS) for detecting treatment effects of common OTC analgesics and a common prescription analgesic in subjects with knee osteoarthritis.

Phase

2.08 miles

Learn More »

Safety and Efficacy of KPI-121 in Subjects With DED

This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle in subjects with dry eye disease.

Phase

2.08 miles

Learn More »

Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP-301)

This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and a 2-week post-treatment follow-up period. This is an outpatient study ...

Phase

2.08 miles

Learn More »